Exceptionally Long Recurrence-Free Survival in a Male Patient With Fibrolamellar Hepatocellular Carcinoma

Fibrolamellar hepatocellular carcinoma (FLHCC) accounts for less than 1% of all primary liver cancers. Due to an absence of known risk factors, most individuals are diagnosed at advanced stages of disease. Subsequently, these tumors carry a 30%-50% mortality rate and a 33%-100% recurrence rate in those treated with curative intent. Here, we describe an incidental discovery of an FLHCC tumor in a young male patient, who following surgical resection has remained recurrence free for over 11 years. This exceptionally long recurrence-free survival highlights the advantage of early-stage detection, the benefit of complete tumor resection, and further underscores the importance of regular postresection cancer surveillance.